Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 645,587 shares of the medical research company’s stock after selling 13,747 shares during the period. Edwards Lifesciences comprises about 0.8% of Edmond DE Rothschild Holding S.A.’s holdings, making the stock its 28th largest position. Edmond DE Rothschild Holding S.A. owned 0.11% of Edwards Lifesciences worth $47,793,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $29,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences during the 4th quarter worth $46,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.4 %

Edwards Lifesciences stock opened at $70.90 on Monday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.73. The firm has a market capitalization of $41.68 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock’s fifty day moving average is $71.49 and its two-hundred day moving average is $70.53. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Morgan Stanley upped their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,553 shares of company stock worth $4,513,064 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.